Critical Analysis: Osiris Therapeutics (OSIR) and Aevi Genomic Medicine (GNMX)

Osiris Therapeutics (NASDAQ: OSIR) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Osiris Therapeutics and Aevi Genomic Medicine, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Osiris Therapeutics	0	0	0	0	N/A
Aevi Genomic Medicine	0	1	1	0	2.50

Aevi Genomic Medicine has a consensus target price of $4.25, indicating a potential upside of 229.46%. Given Aevi Genomic Medicine’s higher probable upside, analysts clearly believe Aevi Genomic Medicine is more favorable than Osiris Therapeutics.

Profitability

This table compares Osiris Therapeutics and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Osiris Therapeutics	-2.60%	-3.13%	-2.59%
Aevi Genomic Medicine	N/A	-125.94%	-106.93%

Earnings & Valuation

This table compares Osiris Therapeutics and Aevi Genomic Medicine’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Osiris Therapeutics	$86.60 million	2.41	$4.41 million	N/A	N/A
Aevi Genomic Medicine	N/A	N/A	-$37.80 million	($1.02)	-1.26

Osiris Therapeutics has higher revenue and earnings than Aevi Genomic Medicine.

Institutional & Insider Ownership

19.9% of Osiris Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Aevi Genomic Medicine shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by insiders. Comparatively, 24.8% of Aevi Genomic Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Osiris Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Summary

Osiris Therapeutics beats Aevi Genomic Medicine on 6 of the 10 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.